Related Experiment Video
Updated: Jul 11, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma
Bryan Gardam1,2, Tessa Gargett1,2,3, Michael P Brown1,2,3
1Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Abstract:
Glioblastoma is an aggressive primary brain tumor that has seen few advances in treatments for over 20 years. In response to this desperate clinical need, multiple immunotherapy strategies are under development, including CAR-T cells, immune checkpoint inhibitors, oncolytic viruses and dendritic cell vaccines, although these approaches are yet to yield significant clinical benefit. Potential reasons for the lack of success so far include the immunosuppressive tumor microenvironment, the blood-brain barrier, and systemic changes to the immune system driven by both the tumor and its treatment. Furthermore, while T cells are essential effector cells for tumor control, dendritic cells play an equally important role in T cell activation, and emerging evidence suggests the dendritic cell compartment may be deeply compromised in glioblastoma patients. In this review, we describe the immunotherapy approaches currently under development for glioblastoma and the challenges faced, with a particular emphasis on the critical role of the dendritic cell-T cell axis. We suggest a number of strategies that could be used to boost dendritic cell number and function and propose that the use of these in combination with T cell-targeting strategies could lead to successful tumor control.
Insights
Glioblastoma immunotherapy faces challenges due to the tumor microenvironment and blood-brain barrier. Enhancing dendritic cell function alongside T cell strategies may improve glioblastoma treatment outcomes.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Therapy
Background:
- Glioblastoma is an aggressive brain tumor with limited treatment progress.
- Current immunotherapies (CAR-T, checkpoint inhibitors, oncolytic viruses, dendritic cell vaccines) show minimal clinical benefit.
- Key challenges include the immunosuppressive tumor microenvironment, blood-brain barrier, and systemic immune alterations.
Purpose of the Study:
- To review current glioblastoma immunotherapies and their challenges.
- To emphasize the critical role of the dendritic cell-T cell axis in glioblastoma.
- To propose strategies for enhancing dendritic cell function to improve immunotherapy efficacy.
Main Methods:
- Literature review of glioblastoma immunotherapy.
- Analysis of the immunosuppressive tumor microenvironment.
- Evaluation of dendritic cell and T cell interactions in glioblastoma.
Main Results:
- Immunotherapy for glioblastoma has yielded limited success.
- Dendritic cells are crucial for T cell activation but appear compromised in glioblastoma patients.
- The tumor microenvironment and blood-brain barrier impede T cell-mediated tumor control.
Conclusions:
- Boosting dendritic cell number and function is critical for effective glioblastoma immunotherapy.
- Combining enhanced dendritic cell strategies with T cell-targeting therapies offers a promising approach.
- Future research should focus on overcoming glioblastoma's immunosuppressive mechanisms via dendritic cell modulation.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
